On January 12, 2025, DM002, a first-in-class bispecific antibody-drug conjugate (ADC) targeting HER3 and MUC1-C independently developed by Doma Biopharmaceutical (Suzhou) Co., Ltd., officially obtained Investigational New Drug (IND) approval from the U.S. FDA, paving the way for Phase I clinical trials. DM002 marks the third bispecific ADC candidate from Doma to secure FDA IND clearance.

On November 28, 2024, DM005, a Class 1 innovative drug independently developed by Doma Biopharmaceutical (Suzhou) Co., Ltd. — an EGFR/c-MET bispecific antibody-drug conjugate (bsADC) for injection — had its new clinical trial application approved by China's National Medical Products Administration (NMPA), and patient enrollment has commenced in China.

October 9, 2024 —— Xadcera Biopharmaceutical (Suzhou) Co., Ltd., a subsidiary of Doma, announced that its self-developed Class 1 innovative drug, DM001 (EGFR/TROP2 bispecific antibody-drug conjugate [ADC] for injection), has received the Clinical Trial Approval Notice (2024LP02269) from Chinese regulatory authorities.

On August 29th, 2024, Doma’s second bispecific ADC asset, DM005, officially received IND clearance from U.S. FDA and about to begin global phase Ⅰ trial.